Abstract 100P
Background
Rapid diagnostic services (RDS) are a two-week wait pathway for patients with non-specific symptoms (e.g., weight loss and fatigue), concerning of malignancy, that do not fulfil criteria for a site-specific cancer referral. Notoriously, patients without clear red flag symptoms have longer time to diagnosis and worse outcomes. RDS are being expanded across England to provide a new referral route for this cohort of patients to improve time to diagnosis and the patient journey. This study aimed to create a cancer risk stratification tool based on levels of standard serum biomarkers to help clinicians triage patients attending Guy’s RDC.
Methods
We analysed a panel of standard serum biomarkers assessed at referral for patients seen at Guy´s RDC between December 2016 and April 2022. Latent class analysis (LCA) was applied to investigate classes of individuals characterized based on their biomarker values (according to medical cut-offs), which were then examined as predictors of cancer using multivariate logistic regression. The abnormal biomarkers identified within LCA class with higher risk of cancer were used to create a scoring system, which was then developed into a cancer stratification tool.
Results
LCA identified four biomarker profiles: 1) normal values for all markers (51% of population); 2) abnormal values for haemoglobin, creatinine, and inflammatory markers (28%); 3) abnormal values for neutrophil to lymphocyte ratio, neutrophils, and inflammatory markers (12%); 4) abnormal values for multiple (n=10) markers (8%). Compared with class 1, class 4 had an increased risk of cancer (Odds ratio (OR) 6.33; 95% Confidence Interval (CI) 5.92-6.77). Based on the biomarkers identified in class 4 we created a score giving one point to each abnormal biomarker. A score of >=2 was associated with an increased risk of cancer (OR 3.09; 95%CI 2.91-3.27), as compared to a score of <2 (Area under the curve for test-training split: 0.68, C-index: 0.7).
Conclusions
Our innovative approach to triage patients with non-specific symptoms in the RDC for cancer diagnosis suggests that a combination of 10 standard biomarkers could be used to help facilitate a more efficient diagnosis of cancer when presenting with vague symptoms.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract